Cytek Biosciences (CTKB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Cytek Biosciences (CTKB) is Neutral.

The composite score behind that read is -0.01, weighing +0.30 of bullish evidence against -0.17 bearish.

Cytek Biosciences last closed at $6.09, +3.75% on the session.

Against the IVW growth benchmark the position is +2.83% over the forecast window.

The read is built from 11 underlying insights — 3 bullish and 8 bearish.

Agreement across those insights is 73%.

16 graded predictions for CTKB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Cytek Biosciences in the 26th percentile on return on equity, where 100 is best.

Cytek Biosciences is classified under Health Care / Life Sciences Tools & Services, with a market capitalisation of $763.00M.

StockMap tracks Cytek Biosciences as the 31st largest of the 39 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 34 Neutral, 4 Moderate Underperform and 1 Strong Underperform.

On that composite Cytek Biosciences ranks 9th of 39 in the group, against a group median of -0.08.